BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kado A, Tsutsumi T, Enooku K, Fujinaga H, Ikeuchi K, Okushin K, Moriya K, Yotsuyanagi H, Koike K. Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells. J Gastroenterol 2019;54:730-41. [PMID: 30830270 DOI: 10.1007/s00535-019-01565-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Petrescu M, Vlaicu SI, Ciumărnean L, Milaciu MV, Mărginean C, Florea M, Vesa ȘC, Popa M. Chronic Inflammation—A Link between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue. Medicina 2022;58:641. [DOI: 10.3390/medicina58050641] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Chung KW, Cho YE, Kim SJ, Hwang S. Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis. Arch Pharm Res 2022. [PMID: 35391713 DOI: 10.1007/s12272-022-01379-1] [Reference Citation Analysis]
3 Batista ES, da Silva Rios T, Muñoz VR, Jesus JS, Vasconcelos MM, da Cunha DT, Marques-Rocha JL, Nakandakari SCBR, Lara R, da Silva ASR, Pauli JR, Ropelle ER, Mekary RA, de Moura LP, Camargo EA, Cintra DE. Omega-3 mechanism of action in inflammation and endoplasmic reticulum stress in mononuclear cells from overweight non-alcoholic fatty liver disease participants: study protocol for the "Brazilian Omega Study" (BROS)-a randomized controlled trial. Trials 2021;22:927. [PMID: 34922604 DOI: 10.1186/s13063-021-05702-x] [Reference Citation Analysis]
4 Lin SZ, Fan JG. Peripheral immune cells in NAFLD patients: A spyhole to disease progression. EBioMedicine 2021;75:103768. [PMID: 34929490 DOI: 10.1016/j.ebiom.2021.103768] [Reference Citation Analysis]
5 Seike T, Mizukoshi E, Yamada K, Okada H, Kitahara M, Yamashita T, Arai K, Terashima T, Iida N, Fushimi K, Yamashita T, Sakai Y, Honda M, Harada K, Kaneko S. Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. J Gastroenterol 2020;55:701-11. [PMID: 32124081 DOI: 10.1007/s00535-020-01679-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]